SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience

Immunocompromised patients experience reduced vaccine effectiveness and are at higher risk for coronavirus disease 19 (COVID-19) death. Pre-exposure prophylaxis (PrEP) aims to protect these patients. So far, only tixagevimab/cilgavimab is authorized for use as PrEP. This paper aims to provide real-w...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	David Totschnig, Max Augustin, Iulia Niculescu, Hermann Laferl, Sonja Jansen-Skoupy, Clara Lehmann, Christoph Wenisch, Alexander Zoufaly
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2022-10-01
Цуврал:	Viruses
Нөхцлүүд:	SARS-CoV-2 PrEP pre-exposure prophylaxis immunocompromised patients sotrovimab tixagevimab/cilgavimab
Онлайн хандалт:	https://www.mdpi.com/1999-4915/14/10/2278
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!